Abbott Laboratories [NYSE: ABT] loss -1.10% on the last trading session, reaching $113.77 price per share at the time. The company report on May 24, 2022 that Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Abbott to release limited quantities of EleCare® branded specialty formulas.
Product will be released immediately free of charge to children in need.
Abbott Laboratories represents 1.76 billion in outstanding shares, while the company has a total market value of $197.80 billion with the latest information. ABT stock price has been found in the range of $111.83 to $115.16.
If compared to the average trading volume of 5.53M shares, ABT reached a trading volume of 5258080 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $140.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 02, 2022. While these analysts kept the previous recommendation, UBS raised their target price from $138 to $142. The new note on the price target was released on January 27, 2022, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another drop from $150 to $143, while Raymond James kept a Outperform rating on ABT stock. On January 27, 2022, analysts decreased their price target for ABT shares from 157 to 151.
The Average True Range (ATR) for Abbott Laboratories is set at 3.27, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 4.44. The Price to Book ratio for the last quarter was 5.66, with the Price to Cash per share for the same quarter was set at 4.69. Price to Free Cash Flow for ABT in the course of the last twelve months was 40.22 with Quick ratio for the last quarter at 1.40.
Trading performance analysis for ABT stock
Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.67. With this latest performance, ABT shares dropped by -5.20% in over the last four-week period, additionally sinking by -9.17% over the last 6 months – not to mention a drop of -3.91% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 49.78, with the RSI for the last a single of trading hit 53.20, and the three-weeks RSI is set at 48.02 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 116.77, while it was recorded at 113.44 for the last single week of trading, and 123.95 for the last 200 days.
Abbott Laboratories [ABT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +21.36 and a Gross Margin at +53.89. Abbott Laboratories’s Net Margin is presently recorded at +16.35.
Return on Equity for this stock inclined to 20.53, with Return on Assets sitting at 9.53.
Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.90.
Abbott Laboratories [ABT]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 11.53%.
An analysis of insider ownership at Abbott Laboratories [ABT]
There are presently around $148,341 million, or 75.40% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 151,288,441, which is approximately 1.432% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 132,854,732 shares of the stock with an approximate value of $15.28 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $9.28 billion in ABT stock with ownership of nearly -4.098% of the company’s market capitalization.
Positions in Abbott Laboratories stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,251 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 49,096,746 shares. Additionally, 1,252 investors decreased positions by around 62,476,298 shares, while 418 investors held positions by with 1,178,016,606 shares. The mentioned changes placed institutional holdings at 1,289,589,650 shares, according to the latest SEC report filing. ABT stock had 146 new institutional investments in for a total of 4,964,182 shares, while 163 institutional investors sold positions of 7,349,722 shares during the same period.